Condition: Growth Hormone Deficiency · Sponsor: Ascendis Pharma Endocrinology Division A/S
The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care
This description comes directly from the study's public registry record.
Deborah Bowlby · +1 844-442-7236 · Skybright_contact@ascendispharma.com
Always discuss trial participation with your own doctor first.
| Ascendis Investigational Site | Phoenix, Arizona, United States | Recruiting |
| Ascendis Investigational Site | Orange, California, United States | Recruiting |
| Ascendis Investigational Site | Sacramento, California, United States | Recruiting |
| Ascendis Investigational Site | San Francisco, California, United States | Recruiting |
| Ascendis Pharma Investigational Site | Centennial, Colorado, United States | Recruiting |
| Ascendis Investigational Site | Washington D.C., District of Columbia, United States | Recruiting |
| Ascendis Investigational Site | Orlando, Florida, United States | Recruiting |
| Ascendis Investigational Site | Orlando, Florida, United States | Recruiting |
| Ascendis Investigational Site | Tampa, Florida, United States | Recruiting |
| Ascendis Investigational Site | Sandy Springs, Georgia, United States | Recruiting |
| Ascendis Investigational Site | Boise, Idaho, United States | Recruiting |
| Ascendis Investigational Site | Indianapolis, Indiana, United States | Recruiting |
+ 15 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05820672